Abstract

As the powerhouse of the cells, mitochondria play a very important role in ensuring that cells continue to function. Mitochondrial dysfunction is one of the main factors contributing to the development of cardiomyopathy in diabetes mellitus. In early development of diabetic cardiomyopathy (DCM), patients present with myocardial fibrosis, dysfunctional remodeling and diastolic dysfunction, which later develop into systolic dysfunction and eventually heart failure. Cardiac mitochondrial dysfunction has been implicated in the development and progression of DCM. Thus, it is important to develop novel therapeutics in order to prevent the progression of DCM, especially by targeting mitochondrial dysfunction. To date, a number of studies have reported the potential of phenolic acids in exerting the cardioprotective effect by combating mitochondrial dysfunction, implicating its potential to be adopted in DCM therapies. Therefore, the aim of this review is to provide a concise overview of mitochondrial dysfunction in the development of DCM and the potential role of phenolic acids in combating cardiac mitochondrial dysfunction. Such information can be used for future development of phenolic acids as means of treating DCM by alleviating the cardiac mitochondrial dysfunction.

Highlights

  • For the past 50 years, our knowledge on the pathophysiology of cardiac failure has advanced significantly

  • Suppress oxidative mitochondrial injury induced by doxorubicin and hypoxia via inhibition of Bcl2-interacting protein 3 (Bnip3)

  • Protects mitochondria against toxicity induced by bevacizumab, an anthracycline agent, by either its antioxidant properties or indirectly via maintenance of mitochondrial complex II activity

Read more

Summary

Introduction

For the past 50 years, our knowledge on the pathophysiology of cardiac failure has advanced significantly. It is estimated that 451 million people are suffering with diabetes worldwide, and the number is forecasted to climb up to 631 million by year 2045, in low- and middle-income countries [2]. Both type 1 (juvenile-onset or insulin-dependent diabetes, T1DM) and type 2 (adult-onset or non-insulin-dependent diabetes, T2DM) diabetes mellitus patients are at greater risk of developing heart disease. Developing cardiovascular disease is the most harmful consequence of diabetes mellitus, and the risk of cardiovascular complications is doubled in patients with diabetes compared to non-diabetic populations [3]

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call